Dublin, Feb. 18, 2026 (GLOBE NEWSWIRE) -- The "PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2026" has been added to ResearchAndMarkets.com's offering.
The report offers exhaustive insights into the global developments in PD-1 and PD-L1 inhibitors, covering over 180 companies and 200 drugs. This document evaluates therapeutics by product type, stage, route of administration, and molecule type, also highlighting inactive pipelines.
Geographical Coverage
PD-1 and PD-L1 inhibitors, pivotal components of immunotherapy, enhance the immune system's capability against cancer cells. By blocking the interaction between PD-1 receptors on T cells and PD-L1 on tumor cells, these inhibitors reinvigorate the immune response, offering improved outcomes in cancers like melanoma and lung cancer. Key drugs in this class, such as nivolumab and pembrolizumab, are crucial in reactivating T cell involvement and overcoming cancer evasion mechanisms.
Recent Updates:
- In February 2025, Innovent Biologics' IBI363 received FDA Fast Track Designation for advanced squamous non-small cell lung cancer post immunotherapy and chemotherapy.
- Shanghai Henlius Biotech's HLX43 completed Phase II (February 2025).
- Pfizer's sasanlimab met primary endpoints in its Phase III CREST trial (January 2025).
- AstraZeneca's Rilvegostomig approved for a Phase III clinical study (December 2024).
- FDA widened Jemperli's approval for endometrial cancer treatment (August 2024).
Company Profiles:
- Merck - Known globally for oncology advances, Merck, through Keytruda, has achieved significant success in treating cancers like melanoma, NSCLC, and more.
- GSK - Leveraging Jemperli in ongoing research, GSK emphasizes substantial R&D in oncology across multiple cancer types.
Pipeline Highlights:
- AstraZeneca - Rilvegostomig, a bi-specific antibody, is under Phase III trials targeting lung carcinoma and gastric cancers.
- Pfizer - Sasanlimab, a PD-1 inhibitor, is in the Phase III trial stage for bladder cancer treatment.
- Incyte Corporation - INCB 099280, an orally administered PD-L1 inhibitor, is advancing through Phase II trials for squamous cell carcinoma.
- Suzhou Zelgen Biopharmaceuticals - ZG005 targets PD-1 and TIGIT, showing promise in Phase II for hepatocellular carcinoma.
- ImmVira Pharma - C5252, developed via the OvPENS platform, is a next-gen oncolytic virus therapy in Phase I for glioblastoma.
The competitive report includes a comprehensive commercial assessment, analyzing collaborations and licensing trends. Additionally, it covers unmet needs and the emerging therapeutic landscape, providing critical insights into various treatment stages and technological innovations.
Key Topics Covered:
Introduction
Executive Summary
PD-1 and PD-L1 Inhibitors: Overview
- Introduction
- Structure
- Mechanism of Action
- Programmed cell death 1 receptor
- Applications
PD-1 and PD-L1 Inhibitors - Analytical Perspective: In-depth Commercial Assessment
- PD-1 and PD-L1 Inhibitors Collaboration Analysis by Companies
Competitive Landscape
- Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
PD-1 and PD-L1 Inhibitors: Company and Product Profiles (Marketed Therapies)
Merck
- Company Overview
KEYTRUDA
- Product Description
- Research and Development Activities
- Product Developmental Activities
PD-1 and PD-L1 Inhibitors: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Phase III)
- Comparative Analysis
AstraZeneca
- Company Overview
Rilvegostomig
- Product Description
- Research and Development Activities
- Product Developmental Activities
Mid Stage Products (Phase II)
- Comparative Analysis
Suzhou Zelgen Biopharmaceuticals
- Company Overview
ZG005
- Product Description
- Research and Development Activities
- Product Developmental Activities
Early Stage Products (Phase I)
- Comparative Analysis
ImmVira Pharma
- Company Overview
C5252
- Product Description
- Research and Development Activities
- Product Developmental Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Company Name
- Company Overview
Product Name
- Product Description
- Research and Development Activities
- Product Developmental Activities
Inactive Products
- Comparative Analysis
PD-1 and PD-L1 Inhibitors- Unmet needs
PD-1 and PD-L1 Inhibitors - Market drivers and barriers
Companies Featured
- GSK
- Roche
- Merck
- Pfizer
- CStone Pharmaceuticals
- Astrazeneca
- Incyte Corporation
- Agenus
- ImmVira Pharma
- Suzhou Zelgen Biopharmaceuticals
For more information about this report visit https://www.researchandmarkets.com/r/d9cqbr
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.